New artificial intelligence algorithms are developed to facilitate the diagnosis and treatment of cancerous tumors that are difficult to interpret clinically.
After FDA rejection, Sanofi and Regeneron’s Dupixent succeeds in late-stage trial of chronic hives
Sanofi and Regeneron’s blockbuster drug Dupixent successfully treated patients with chronic spontaneous urticaria, an inflammatory skin disease, in a late-stage trial, the companies announced on
September 11, 2024